{"product_id":"coronavirus-disease-2019-covid-19-shailendra-k-saxena-9789811548161","title":"Coronavirus Disease 2019 (Covid-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics","description":"\u003cb\u003eChapter 1\u003c\/b\u003e_Global trends in epidemiology of Coronavirus Disease 2019 (COVID-19). -Chapter 1.1. Introduction. -Chapter 1.2. 21\u003csup\u003est \u003c\/sup\u003ecentury SARS-CoV-2 outbreaks, epidemics. -Chapter 1.3.Worldwide surveillance systems. -Chapter 1.4. Regions of potential threat. -Chapter 1.5. Pandemic SARS-CoV-2. -Chapter 1.6. Conclusions. -Chapter 1.7. Future Perspectives. -Chapter 1.8. References. -\u003cb\u003eChapter 2\u003c\/b\u003e_Genome organization and Pathogenesis of novel Coronavirus 2019 (SARS-CoV-2)\u003cb\u003e.\u003c\/b\u003e -Chapter 2.1. Introduction\u003cb\u003e.\u003c\/b\u003e -Chapter 2.2. Structure and genome of SARS-CoV-2\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3. Replication and life cycle of virus\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.1 Attachment\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.2.Entry\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.3. Receptors\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.4. Uncoating\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.5. Synthesis of viral RNA\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.6. Viral proteins \u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.7. Egress\u003cb\u003e.\u003c\/b\u003e -Chapter 2.4. Conclusions\u003cb\u003e.\u003c\/b\u003e -Chapter 2.5. Future Perspectives\u003cb\u003e. \u003c\/b\u003e-\u003cb\u003eChapter 3\u003c\/b\u003e_Host immune response against human SARS-CoV-2 infection.\u003cb\u003e \u003c\/b\u003e-Chapter 3.1. Introduction\u003cb\u003e.\u003c\/b\u003e -Chapter 3.2. Immune response\u003cb\u003e.\u003c\/b\u003e -Chapter 3.3. Humoral immune response\u003cb\u003e.\u003c\/b\u003e -Chapter 3.4.Cellular immune response\u003cb\u003e.\u003c\/b\u003e -Chapter 3.5. Conclusions\u003cb\u003e.\u003c\/b\u003e -Chapter 3.6. Future Perspectives\u003cb\u003e.\u003c\/b\u003e -\u003cb\u003eChapter 4\u003c\/b\u003e_Emergence and Re-emergence of SARS Coronaviruses\u003cb\u003e.\u003c\/b\u003e -Chapter 4.1. Introduction\u003cb\u003e.\u003c\/b\u003e -Chapter 4.2. SARS-CoV to SARS-CoV-2: RNA recombination, antigenic shift and antigenic drift\u003cb\u003e.\u003c\/b\u003e -Chapter 4.3. Conclusions\u003cb\u003e.\u003c\/b\u003e -Chapter 4.4. Future Perspectives\u003cb\u003e.\u003c\/b\u003e\u003cb\u003e -Chapter 5_\u003c\/b\u003eTransmission cycle of SARS-CoV and SARS-CoV-2. . -Chapter 5.1. Introduction. -Chapter 5.2. Coronavirus Transmission cycle. -Chapter 5.2.1. Transmission among animals. -Chapter 5.2.2. Transmission in animals to human. -Chapter 5.2.3.Transmission among humans. -Chapter 5.2.4. Other hosts. -Chapter 5.3. Conclusions. -Chapter 5.4. Future Perspectives. -\u003cb\u003eChapter 6_\u003c\/b\u003ePreparing for the perpetual challenges of pandemics of Coronavirus infections with special focus on SARS-CoV-2. -Chapter 6.1. Introduction. -Chapter 6.2. Strategies for pandemic preparedness for Coronavirus. -Chapter 6.2.1. Updated Surveillance system. -Chapter 6.2.2. Strategies for implementation of laboratory diagnostic services during pandemics. -Chapter 6.2.3. Management of bulk vaccines, antiviral drugs. -Chapter 6.3. Promoting facilities for treatment and hospitalisation, healthcare personnel, maintenance of hygiene and disinfection during pandemics. -Chapter 6.3.1.Global management strategies of Coronavirus infection. -Chapter 6.3.2.Economic Consequences of pandemic risk. -Chapter 6.3.3.Conclusions. -Chapter 6.3.4. Future Perspectives. -\u003cb\u003eChapter 7.\u003c\/b\u003e Clinical manifestations and diagnosis of human SARS-CoV-2 infection. . -Chapter 7.1. Introduction. -Chapter 7.2. General Symptoms of SARS-CoV-2 infection. -Chapter 7.3. Clinical Course. -Chapter 7.4. Clinical complications. -Chapter 7.5. Diagnosis of SARS-CoV-2. -Chapter 7.6. Conclusions. -Chapter 7.7. Future Perspectives\u003cb\u003e. -Chapter 8.\u003c\/b\u003e Treatment and Drugs for SARS-CoV-2. . -Chapter 8.1. Introduction. -Chapter 8.2. Antiviral drugs for SARS-CoV-2. -Chapter 8.3. Current available drugs, Pharmacokinetics, Toxicity, Efficacy, Resistance, Drug Interactions, Recommendations for Use. . -Chapter 8.4. Complementary and alternative medicines for SARS-CoV-2. . -Chapter 8.5. Conclusions. -Chapter 8.6. Future Perspectives\u003cb\u003e. -Chapter 9.\u003c\/b\u003e Prevention and control strategies for SARS-CoV-2 infection. . -Chapter 9.1. Introduction. -Chapter 9.2. SARS-CoV-2 vaccine development. -Chapter 9.3. Types of Coronavirus vaccines. -Chapter 9.4. Efficacy and effectiveness of Coronavirus vaccines. -Chapter 9.5. Control strategies of Coronavirus infection. -Chapter 9.6. Conclusions\u003cbr\u003e\u003cbr\u003e\u003cb\u003eAuthor:\u003c\/b\u003e Shailendra K. Saxena\u003cbr\u003e\u003cb\u003eISBN-10:\u003c\/b\u003e 9811548161\u003cbr\u003e\u003cb\u003eISBN-13:\u003c\/b\u003e 9789811548161\u003cbr\u003e\u003cb\u003ePublisher:\u003c\/b\u003e Springer\u003cbr\u003e\u003cb\u003eLanguage:\u003c\/b\u003e English\u003cbr\u003e\u003cb\u003ePublished:\u003c\/b\u003e 04\/30\/2021\u003cbr\u003e\u003cb\u003ePages:\u003c\/b\u003e 213\u003cbr\u003e\u003cb\u003eFormat:\u003c\/b\u003e Paperback\u003cbr\u003e\u003cb\u003eWeight:\u003c\/b\u003e 0.74lbs\u003cbr\u003e\u003cb\u003eSize:\u003c\/b\u003e 9.21h x 6.14w x 0.50d","brand":"Shailendra K. Saxena","offers":[{"title":"Paperback","offer_id":43993034916095,"sku":"9789811548161","price":199.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/2982\/9887\/files\/img_57bb7332-da13-4495-be38-ad5fc26e587c.jpg?v=1683322163","url":"https:\/\/www.whiterainbookhouse.com\/products\/coronavirus-disease-2019-covid-19-shailendra-k-saxena-9789811548161","provider":"WR Book House","version":"1.0","type":"link"}